


09776125  
7/22/04



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 0 894 503 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
03.02.1999 Bulletin 1999/05

(51) Int. Cl.<sup>6</sup>: **A61L 27/00**

(21) Application number: **98201865.7**

(22) Date of filing: **08.06.1998**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(72) Inventor:  
**Stinson, Jonathan Swift  
Plymouth, Minnesota 55447 (US)**


(74) Representative: **Jansen, Götz  
Schneider (Europe) GmbH,  
Ackerstrasse 6  
8180 Bülach (CH)**

(30) Priority: **01.08.1997 US 904951**

(71) Applicant: **SCHNEIDER (USA) INC.  
Plymouth, Minnesota 55442 (US)**

(54) **Bioabsorbable marker having radiopaque constituents and method of using same**

(57) A temporary bioabsorbable-radiopaque marker (14) for use on an implantable endoprosthesis (16). The bioabsorbable-radiopaque marker (14) is adapted to be disposed on or adjacent an implantable endoprosthesis (16) in a body lumen (12) for a predetermined amount of time until the bioabsorbable and radiopaque materials are absorbed or dispersed in the body.



EP 0 894 503 A2

**Description****Background of the Invention**

5 [0001] This invention relates generally to a bioabsorbable marker having radiopaque constituents "bioabsorbable-radiopaque marker" for use on an implantable endoprosthesis such as a stent. The bioabsorbable marker includes dispersible radiopaque constituents which are not bioabsorbable or degradable, but are excreted from the body or stored in the body.

10 [0002] Implantable endoprostheses including stents, stent-grafts, and grafts are used in percutaneous transluminal coronary angioplasty and in other medical procedures to repair and support diseased or damaged arteries and body lumens. Grafts are implanted to cover or bridge leaks or dissections in vessels. Stent-grafts are stents which generally have a porous coating attachment. Unsupported grafts are porous tubes which are typically implanted by surgical cut-down.

15 [0003] In order to visualize the passage and placement of the implantable endoprosthesis in arteries and body lumens, may surgical procedures are performed with the aid of fluoroscopic angiography. The surgical delivery device and implantable endoprosthesis may be visualized if they are radiopaque and offer radiographic contrast relative to the body. For example, X-ray radiation may be used to visualize surgical delivery devices and deployment of the implant in the body. Also, radiographic contrast solution may be injected into the body lumen so that the lumen may be seen in the fluoroscopic image.

20 [0004] In order for the Implantable endoprosthesis to be radiopaque, it must be made from a material possessing radiographic density higher than surrounding host tissue and have sufficient thickness to affect the transmission of x-rays to produce contrast in the image. Reference is made to the clad composite stent shown in United States Patent No. 5,630,840. An implantable endoprosthesis may be made of metals including tantalum, or platinum having relatively high radiographic densities. Other metals such as stainless steel, superalloys, nitinol, and titanium having lower radiographic densities may also be used. Reference is made to implantable devices shown in United States Patents Nos. 4,655,771; 4,954,126; and 5,061,275.

25 [0005] An implantable polymeric endoprosthesis is generally radiolucent and does not possess sufficient radiographic density to be easily imaged by fluoroscopy. To improve the imaging of such polymeric materials, polymers may be mixed with radiopaque filler materials prior to molding or extruding in order to enhance the radiographic density. However, a disadvantage of using fillers with polymers is that changes in the properties of the polymer may occur. For example, the additions of fillers may reduce the strength or ductility of the polymer.

30 [0006] There is a need for a improved bioabsorbable-radiopaque marker for use in medical devices, particularly in temporary medical devices having low radiopacity. The need to improve the radiopacity of a relatively low radiopaque implantable endoprosthesis or to improve imaging in low radiopaque conditions is particularly important for surgery, micro-surgery, neurosurgery, and conventional angioplasty procedures performed under fluoroscopy. Physicians are constantly being challenged to place small implants at specific intraluminal locations. Various devices having radiopacity are known in the art such as shown in United States Patents Nos. 4,447,239; 5,354,257; and 5,423,849.

35 [0007] All documents cited herein, including the foregoing, are incorporated herein by reference in their entireties for all purposes.

**Summary of the Invention**

40 [0008] Accordingly, there is a need for bioabsorbable-radiopaque markers for use on implantable endoprostheses in order to improve radiopacity and the locatability of an endoprosthesis during various medical procedures. Providing temporary radiopacity is especially advantageous for implantable endoprostheses having little or no radiopacity. The bioabsorbable-radiopaque markers allow radiographic identification of one or more locations of interest on an implantable endoprosthesis. Bioabsorbable-radiopaque markers in the fabric or covering materials of an implantable endoprosthesis are advantageous for indicating the location of the fabric or covering during implantation.

45 [0009] Alternative uses include threading the markers: adjacent a helical strand in the implantable endoprosthesis; circumferentially around the implantable endoprosthesis; or in a straight line in the axial direction of the implantable endoprosthesis. One or more bioabsorbable-radiopaque markers may be used on the implantable endoprosthesis having little or no radiopacity. After implantation, the bioabsorbable-radiopaque marker may be absorbed, dissolved, or excreted from the body so as not to effect the function of the endoprosthesis.

50 [0010] A disadvantage of certain permanent radiopaque markers is that they may compromise structural integrity, may not be biocompatible or biostable, and may be more thrombogenic than the implantable endoprosthesis.

55 [0011] The bioabsorbable-radiopaque marker of the present invention advantageously allows most any implantable endoprosthesis to have temporary radiopacity over a predetermined portion of its structure, and advantageously assists with proper positioning and locatability of the implantable endoprosthesis in a body lumen.

[0012] Use of the bioabsorbable-radiopaque marker is advantageous because the radiopaque property may be present only for a desired time period on an implantable endoprosthesis. For instance, once the implantable endoprosthesis is implanted, it may be more desirable to image with techniques such as ultrasound, magnetic resonance, and endoscopy and to avoid further radiation exposure to the patient. As the bioabsorbable polymer degrades, radiopaque material simultaneously or subsequently disperses into the body. The dispersion of the radiopaque material from the marker results in a loss of radiopacity in the marker. A predetermined rate of release of the radiopaque material may be designed into the bioabsorbable marker based on degradation of the polymer in the body or the design of the marker structure.

[0013] The bioabsorbable material in the bioabsorbable-radiopaque markers may include polymers or copolymers such as polylactide [poly-L-lactide (PLLA), poly-D-lactide (PDLA)], polyglycolide, polydioxanone, polycaprolactone, polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, poly(hydroxybutyrate), polyanhydride, polyphosphoester, poly(amino acids), poly(alpha-hydroxy acid) or related copolymers materials, each of which have a characteristic degradation rate in the body. For example, polyglycolide and polydioxanone are relatively fast-bioabsorbing materials (weeks to months) and PLA is a relatively slow-bioabsorbing material (months to years). For a PLA member, mass degradation is completed with total absorption of the polymer endoprosthesis in about 1.5 to 3 years after implantation.

[0014] Bioabsorbable resins such as PLLA, PDLA, PGA and others are commercially available from several sources including PURAC America, Inc. of Lincolnshire, Illinois. Radiopaque materials such as barium sulfate and bismuth trioxide are commercially available and compounded with the bioabsorbable resin by New England Urethane, Inc. of North Haven, Connecticut. The bioabsorbable resin or bioabsorbable-radiopaque resin may be extruded into filament by Albany International Research Co. of Mansfield, Massachusetts.

[0015] The bioabsorption rate of the marker may be designed to be fast for applications where acute radiopacity is desired such as during positioning and placement of the implant. Alternatively, the bioabsorption rate may be designed to be slower for applications where the implant must be radiographically imaged for at least a portion of its functional time, for example, in implants where healing may take months. Other bioabsorption rates are also possible. The bioabsorption rate of the marker may be tailored by controlling the type of bioabsorbable polymer; chemical composition of the bioabsorbable polymer; molecular weight of the bioabsorbable polymer; thickness and density of the bioabsorbable polymer, surface area of the marker, exit area for the radiopaque material, and design of the marker structure.

[0016] The degradation products from the bioabsorbable marker and the dispersed radiopaque material are metabolized, excreted, or stored by the body. Metabolism is the chemical process in living cells by which energy is provided for vital processes and activities and new material is assimilated to repair the waste. It is the sum of the processes by which a particular substance is handled in the living body. Excretion is separation and elimination or discharge from the blood or tissues of useless, superfluous, or harmful material that is eliminated from the body.

[0017] The biocompatibility of absorbable polymers during degradation depends upon the rate of accumulation and how well the surrounding tissue or fluid buffers or metabolizes the degradation products. If the products are metabolizable, the rate at which this will occur is dependent upon the blood circulation in the tissue. A well-vascularized lumen wall could buffer and metabolize degradation products as they are released from the implant. This biological process is important to minimize adverse tissue reaction to the degrading implant.

[0018] The degradation products from PLLA and PGA are lactic and glycolic acid, respectively, which are normally present in the human body. The acids are metabolized by cells around the implant. The metabolism process is a citrate cycle which converts the acids to carbon dioxide which is respired out of the body.

[0019] The radiopaque agents added to the bioabsorbable marker are generally insoluble in the body and thus are not metabolizable. If these materials are trapped within tissue, the host generally reacts by encapsulation and acceptance of the biologically inactive particles. If the material is released from the implant into systemic circulation, it will migrate with fluid flow until being excreted or collected and stored by organs or tissue. The idea is to only have small amounts of the radiopaque substances in the implant by incorporating the discrete bioabsorbable-radiopaque marker rather than to load the entire implant with the radiopaque material. Minimization of the amount of radiopaque material which will be liberated from the marker upon absorption of the polymer must be considered when determining the loading percentage based on radiographic and mechanical properties.

[0020] To be radiopaque, the markers should include material having atomic elements of sufficiently high atomic number and be of sufficient thickness to provide sufficient radiopacity for imaging. The bioabsorbable-radiopaque marker may have one or more hollow, cavity, or porous portions wherein radiopaque material may be disposed.

[0021] Attenuation is the change in the number of photons in the incident x-ray beam due to the interaction with an absorber. To image an object implanted in the body, it would be desirable to have the object attenuate x-rays more than body tissue, bone, and fat so that the difference in contrast will be obvious in a radiograph. The difficulty in selecting a radiopaque material for surgical implants is that the material must have desirable radiographic characteristics and biocompatibility.

[0022] In order to make an implant more radiopaque, a substance which absorbs more x-rays can be deposited on or

mixed in with the implant material. If the implant absorbs more x-rays than the surrounding medium (for example tissue in the body), it will be visible as a sharp change in contrast on an x-ray film or fluoroscopy image.

[0023] The fraction of x-ray energy transmitted through the absorber is quantitatively predicted by the following equation described in *The Physics of Radiology*, Fourth Ed., H. Johns, J. Cunningham, 1983, pp.137-142.

$$N = N_0 e^{-\mu x}$$

$N$  = number of photons transmitted through  $x$

$N_0$  = number of photons in the incident beam

$\mu$  = linear attenuation coefficient of the absorber

$x$  = absorber thickness

[0024]  $N/N_0$  would be the fraction of incident x-ray energy that is transmitted through the absorber. A more radiopaque material would have a lesser fraction of transmitted energy than a more radiolucent material. Therefore, to enhance the radiopacity of a material, such as the marker material, it would be desirable to select a material with high x-ray absorbing capability to minimize the fraction of transmitted energy. This radiopacity capability is proportional to the linear attenuation coefficient and the thickness of the absorber material. The higher the attenuation coefficient of the absorber material for a given thickness, the more radiopaque the absorber will be. The attenuation produced by an absorber is dependent upon the number of electrons and atoms present in the absorber. One way of quantifying this absorption characteristic is with the atomic attenuation coefficient which is directly proportional to the linear attenuation coefficient and the atomic number of the absorber element. Radiopacity is therefore generally proportional to the atomic number (number of electrons in the atom) of the material. Candidate materials for enhancing the radiopacity of surgical implants would have higher atomic numbers than the elements present in the body and would have to be biocompatible. The atomic number must be sufficiently high so that relatively small thickness of absorber material can be used in the body. Reference is also made to linear attenuation coefficient described in United States Patent No. 5,628,787. Reference is made to Table 1 which describes a number of elements and their respective atomic numbers and certain linear attenuation coefficients.

Table 1

Element or Material	Atomic Number or Effective Atomic Number	Linear Attenuation Coefficient at 50 KeV, cm <sup>-1</sup>
hydrogen	1	.000028
carbon	6	.417
fat	6.46	.1925
water	7.51	.2245
muscle	7.64	.2330
air	7.78	.00025
nitrogen	7	.00023
oxygen	8	.00028
bone	12.31	.5727
titanium	22	
iron	26	15.2
cobalt	27	18.8
bromine	35	
zirconium	40	
iodine	53	45
barium	56	58
tantalum	73	111
platinum	78	108
gold	79	101
lead	82	88.7
bismuth	83	108

[0025] The elements hydrogen, oxygen, carbon, and nitrogen are commonly found in the body and in polymers, so elements with higher atomic numbers than these should enhance the radiopacity of a polymer implant or marker. Tantalum, zirconium, titanium, barium, bismuth, and iodine are known to be non-toxic in certain concentrations and thus are candidate elements for enhancing radiopacity of a polymer marker in an implant. These elements can be added to the polymer in various loading percentages and the threshold above which the loading causes unsatisfactory changes in the polymer characteristics can be determined through material and device testing. The elements which can be added in quantities sufficient to enhance radiopacity and maintain an acceptable level of polymer properties and which are biocompatible could be utilized in markers. The biocompatible elements with a range of atomic numbers of from about 22 to about 83 and having linear attenuation coefficients in the range of from about 10 to about 120 cm<sup>-1</sup> at 50 KeV should provide enough enhancement in radiopacity without excessive thickness being necessary to be useful in markers. These elements would include at least titanium, vanadium, chromium, iron, cobalt, nickel, copper, bromine, zirconium, niobium, molybdenum, silver, iodine, barium, tantalum, tungsten, platinum, gold, and bismuth. The preferred metallic elements for biocompatibility and radiopacity are titanium, zirconium, tantalum, and platinum. The preferred organic elements for biocompatibility and radiopacity are bromine, iodine, barium, and bismuth. Especially preferred elements are tantalum, platinum, barium, and bismuth because of their high atomic numbers and biocompatibility (atomic numbers from 56 to 83 and linear attenuation coefficients from 30 to 120). Tantalum and platinum are used as stent components and barium sulfate and bismuth trioxide are used as radiopaque enhancements for polymer catheters.

[0026] The bioabsorbable-radiopaque marker may be integrated into a subassembly or a finished implantable endoprosthesis during manufacture. Radiopaque elongate elements may be braided together with non-radiopaque bioabsorbable elongate elements to form a tubular braided stent, or the bioabsorbable and radiopaque elongate elements may be woven into the finished-braided stent.

[0027] The bioabsorbable-radiopaque marker would advantageously add temporary radiopacity to a implantable endoprosthesis such that the temporary marker would not require a medical procedure for removal from the patient.

[0028] In sum the invention relates to an implantable endoprosthesis and bioabsorbable-radiopaque marker system including an implantable endoprosthesis adapted to be disposed in a body lumen and at least one marker. The marker having a proximal end, a distal end, and a thickness. The marker including bioabsorbable material and radiopaque material and is disposed on or adjacent the endoprosthesis. The marker is adapted to degrade *in vivo* whereby the bioabsorbable material is metabolized through or excreted from the body and the radiopaque material is excreted from or stored in the body. The bioabsorbable material may include a polymer or copolymer. The bioabsorbable material may include poly-L-lactide, poly-D-lactide, polyglycolide, polydioxanone, polycaprolactone, and polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, poly(hydroxybutyrate), polyanhydride, polyphosphoester, poly(amino acids), poly(alpha-hydroxy acid) and combinations thereof. The radiopaque material may have a linear attenuation coefficient of from about  $10\text{ cm}^{-1}$  at 50 KeV to about  $120\text{ cm}^{-1}$  at 50 KeV. The marker may have an average thickness of from about 20 microns to about 500 microns and the radiopaque material includes at least one element with an atomic number of from about 22 to about 83. The radiopaque material may include barium sulfate, bismuth trioxide, bromine, iodine, iodide, titanium oxide, zirconium oxide, tantalum, and combinations thereof. The radiopaque material may be an oxide or salt material. One of the bioabsorbable material or radiopaque material may be coated or compounded with the other and the radiopaque material may have a linear attenuation coefficient of from about  $10\text{ cm}^{-1}$  at 50 KeV to about  $120\text{ cm}^{-1}$  at 50 KeV. The marker may have a weight percent of the radiopaque material in the bioabsorbable material of from about 1% to about 80%. The bioabsorbable material may consist of PLLA and the radiopaque material may consist of bismuth trioxide and the weight percent of the bismuth trioxide in the PLLA may be at least about 10%. The bioabsorbable material may consist of PLLA and the radiopaque material may be barium sulfate and the weight percentage of the barium sulfate in the PLLA may be at least about 10%. The marker may substantially degrade in less than about 3 years. "Substantial degradation of the marker" means that the marker has lost at least 50% of its structural strength. It is preferable that the marker lose about 100% of its structural strength. The bioabsorbable material may consist of polylactide and the radiopaque material may consist of barium sulfate, bismuth trioxide, iodine, iodide, and combinations thereof and the marker substantially degrades in from about 1 year to about 2 years. The bioabsorbable material may include poly-L-lactide, poly-D-lactide, polyglycolide, and combinations thereof and the radiopaque material may include barium sulfate, bismuth trioxide, bromine, iodine, iodide, and combinations thereof and the marker substantially degrades in from about 3 months to about 1 year. The bioabsorbable material may include polyglycolide, polygluconate, polydioxanone, and combinations thereof and the radiopaque material may include barium sulfate, bismuth trioxide, bromine, iodine, iodide, and combinations thereof and the marker substantially degrades in from about 1 week to about 3 months. The marker may be a mono-filament multi-filament, thread, ribbon, suture, and combinations thereof. The marker may include one or more hollow, cavity, porous, and combinations thereof portions and the radiopaque material may be disposed therein. The marker may have radiopacity for a predetermined amount of time. The endoprosthesis may be a stent, stent-graft, graft, filter, occlusive device, or valve. The endoprosthesis may have a tubular, radially expandable structure and axially flexible structure including a plurality of the elongate elements which are interwoven in a braid-like configuration.

[0029] The invention also relates to an implantable endoprosthesis and bioabsorbable-radiopaque marker system including an implantable endoprosthesis adapted to be disposed in a body lumen and at least one elongated marker. The marker is adapted to be disposed on or adjacent the endoprosthesis. The marker includes a proximal end, distal end, thickness, bioabsorbable material, and a radiopaque material having a linear attenuation coefficient of from about  $10\text{ cm}^{-1}$  at 50 KeV to about  $120\text{ cm}^{-1}$  at 50 KeV. The marker has at least one hollow, cavity, or porous portion where the radiopaque material may be disposed. The bioabsorbable material at least partially contains the radiopaque material in the marker. The radiopaque material may be a liquid, solid, powder, gel, particle, or combinations thereof.

[0030] The invention also relates to a method of marking a implantable endoprosthesis including: disposing at least one elongate marker on or adjacent to at least a portion of a implantable endoprosthesis. The marker is from about 20 weight percent to about 99 weight percent of a bioabsorbable polymer and from about 1 weight percent to about 80 weight percent of a radiopaque material. The radiopaque material includes liquid or particles, the particles having an average diameter less than about 200 microns and a maximum diameter less than about 400 microns. The radiopaque material has a linear attenuation coefficient of from about  $10\text{ cm}^{-1}$  at 50 KeV to about  $120\text{ cm}^{-1}$  at 50 KeV; disposing the endoprosthesis and marker in a delivery system; inserting the delivery system in a body lumen; deploying the endoprosthesis and marker from the delivery system into a body lumen; and allowing the polymer to bioabsorb or excrete and the radiopaque material to subsequently or simultaneously at least partially disperses from the endoprosthesis.

[0031] The invention also relates to a temporary bioabsorbable-radiopaque marker including a marker having an average thickness less than about 500 microns and consisting of a bioabsorbable material and a radiopaque material, the radiopaque material having a linear attenuation coefficient of from about  $10\text{ cm}^{-1}$  at 50 KeV to about  $120\text{ cm}^{-1}$  at 50 KeV. The marker is adapted to be disposed in a body lumen and degrade *in vivo*. The marker may be elongate and have a proximal end and a distal end.

[0032] The invention also relates to a bioabsorbable-radiopaque marker including a elongate element adapted to be disposed in a body lumen and used as a surgical guide, the element including a bioabsorbable material, a radiopaque material, and combinations thereof. The element has a weight percent, W, of the radiopaque material in the bioabsorbable material, and an average thickness, T, over the length of the elongate element. The weight percent, W, is equal to about:

- (i)  $(10 + ((950 \times T(\text{measured in mm})) - 208.5)) \pm 5$  for radiopaque material having atomic weight 20-100;
  - (ii)  $((950 \times T(\text{measured in mm})) - 208.5) \pm 5$  for radiopaque material having atomic weight of 100 to 150 up to a maximum of 80 weight percentage ; or
  - (iii)  $(((950 \times T(\text{measured in mm})) - 208.5) - 10) \pm 5$  for radiopaque material having atomic weight greater than 150.
- The minimum W is about 1 and the maximum W is about 80.

[0033] The invention also relates to a marker including from about 20 weight percent to but 99 weight percent of a bioabsorbable polymer; and from about 1 weight percent to about 80 weight percent of a radiopaque material. The radiopaque material includes at least one of a liquid or particle having an average particle diameter less than about 8 microns and a maximum particle diameter less than about 10 microns. The radiopaque material has a linear attenuation coefficient of from about  $10 \text{ cm}^{-1}$  at 50 KeV to about  $120 \text{ cm}^{-1}$  at 50 KeV. For vascular system. The preferred average particle size is from about 3 microns to about 6 microns and a maximum particle size of 6 microns. For the digestive system, the average particle size may be from about 100 microns to about 150 microns and a maximum particle size of 400 microns.

[0034] Still other objects and advantages of the present invention and methods of construction of the same will become readily apparent to those skilled in the art from the following detailed description, wherein only the preferred embodiments are shown and described, simply by way of illustration of the best mode contemplated of carrying out the invention. As will be realized, the invention is capable of other and different embodiments and methods of construction, and its several details are capable of modification in various obvious respects, all without departing from the invention. Accordingly, the drawing and description are to be regarded as illustrative in nature, and not as restrictive.

#### Brief Description of the Drawings

[0035]

FIG. 1 is a side view of stent delivery system having a bioabsorbable-radiopaque marker disposed on an implantable endoprosthesis;

FIG. 2 is a side view of the delivery system and a deployed implantable endoprosthesis in a body lumen;

FIGS. 3a, 3b, and 3c are cross-sectional views of three alternative marker dispositions of the bioabsorbable-radiopaque marker on the implantable endoprosthesis at section 3-3 of FIG. 2;

FIG. 4 is a side view of a bioabsorbable-radiopaque marker disposed in a longitudinal pattern on a implantable endoprosthesis;

FIG. 5 is a side view of a bioabsorbable-radiopaque marker disposed in a helical pattern on a implantable endoprosthesis;

FIG. 6 is a side view of a relatively flexible bioabsorbable-radiopaque marker;

FIGS. 7a-7e are cross-sectional views of five alternative bioabsorbable-radiopaque markers at section 7-7 of FIG. 6;

FIGS. 8a-8c are side views of three alternative bioabsorbable-radiopaque markers;

FIG. 9 is a side views of a porous bioabsorbable-radiopaque marker, and

FIGS. 10a-10d are side views of four elongate elements having radiopaque materials therein.

FIG. 11 is a side view illustrating one possible arrangement of discrete bioabsorbable-radiopaque markers disposed on an implantable endoprosthesis;

FIG. 12 is the detail bounded by the dashed-line circle in FIG. 12 illustrating a bioabsorbable-radiopaque marker disposed around on implantable endoprosthesis wire crossing point;

FIG. 13 is a side view illustrating a discrete radiopaque marker; and

FIG. 14 illustrates the discrete bioabsorbable-radiopaque marker positioned on an embolization occlusion coil intra-vascular device.

#### Detailed Description of the Invention

[0036] Reference is made to FIG. 1 illustrating a stent delivery device 10 having one or more bioabsorbable-radiopaque markers 14 disposed in a helical pattern on a implantable endoprosthesis 16. The bioabsorbable-radiopaque

marker 14 is disposed on the endoprosthesis 16 preferably before loading the assembly thereof into the outer tube of a delivery device 10. Reference is made to a delivery device shown in United States Patent No. 5,026,377.

[0037] FIG. 2 illustrates an implantable endoprosthesis 16 having a bioabsorbable-radiopaque markers 14 disposed in a helical pattern thereon in a body lumen 12. Implantable endoprostheses 16 known in the art include stents, stent-grafts, grafts, filters, occlusive devices, valves, and combinations thereof, all may incorporate the bioabsorbable-radiopaque marker 14.

[0038] FIGS. 3a-3c illustrate three alternative locations on a implantable endoprosthesis 16 for disposing the bioabsorbable-radiopaque marker. The bioabsorbable-radiopaque marker 14 may be disposed on portions of the inside surface 17, outside space 19, or be inter-woven or inter-braided about and through the elongated elements of the implantable endoprosthesis 16. The bioabsorbable-radiopaque marker 14 may be disposed on the implantable endoprosthesis 16 in one or more predetermined lengths.

[0039] Reference is made to FIGS. 4 and 5 illustrating the bioabsorbable-radiopaque marker 14 disposed in two alternative patterns on the implantable endoprosthesis 16. FIG. 4 shows the bioabsorbable-radiopaque marker 14 interwoven through the filaments of the endoprosthesis 16 in a relatively longitudinal pattern. Alternatively, the bioabsorbable-radiopaque marker 14 may be interwoven through the filaments of the endoprosthesis 16 in a relatively circumferential pattern. FIG. 5 shows a marker 14 interwoven through the filaments of the endoprosthesis 16 in a relatively helical pattern. Other patterns and dispositions of the bioabsorbable-radiopaque marker 14 on the endoprosthesis 16 are also possible. One or more markers 14 may be temporarily disposed on the implantable endoprosthesis 16 to advantageously provide temporary radiopacity to predetermined locations on the implantable endoprosthesis 16.

[0040] As shown in FIGS. 3a and 3c, the bioabsorbable-radiopaque marker 14 may be disposed to one or more surfaces of the implausible endoprosthesis 16 with a relatively weak bioabsorbable adhesive or gelatin.

[0041] The bioabsorbable-radiopaque marker 14 may include elongate elements such as a ribbon, thread, filament, suture, or combinations thereof. The bioabsorbable-radiopaque marker 14 may be braided to form a rope or cable.

[0042] As the implantable endoprosthesis 16 is deployed from the delivery device 10, the bioabsorbable-radiopaque marker 14 may adjust with the expansion of the implantable endoprosthesis 16, and advantageously provide radiopacity and enhance the viewing of the implantable endoprosthesis 16 position or size during fluoroscopy. Once the implantable endoprosthesis 16 is fully deployed, the delivery device 10 may be removed from the body and the bioabsorbable-radiopaque marker 14 may remain on the implantable endoprosthesis 16 to be bioabsorbed, dissolved, dispersed, or excreted from the body. The bioabsorbable-radiopaque marker 14 may be designed to remain on the implantable endoprosthesis 16 for a predetermined period of time if there is a need for follow-up angiography.

[0043] Reference is made to FIG. 6 illustrating a bioabsorbable-radiopaque marker 14 preferably made from a relatively flexible elongate polymeric material including radiopaque material containing at least one element with an atomic number of from about 22 to about 83. The radiopaque material preferably has a linear attenuation coefficient of from about  $10 \text{ cm}^{-1}$  at 50 KeV to about  $120 \text{ cm}^{-1}$  at 50 KeV.

[0044] FIGS. 7a-7e illustrate alternative cross-sectional embodiments of the bioabsorbable-radiopaque marker 14 taken through the line 7-7 of FIG. 6. FIG. 7a shows a substantially solid member; FIG. 7b shows a hollow member; FIG. 7c shows a member having pores extending radially into the member; FIG. 7d shows a rectangular or ribbon member; and FIG. 7e shows a braided hollow member. Fig. 7e may also be a substantially solid braided member.

[0045] A composite bioabsorbable-radiopaque marker 14 may include a bioabsorbable polymer that is coated, compounded, filled, loaded, or mixed with a radiopaque substance such as iodide, iodine, zirconium oxide, barium sulfate, bismuth trioxide, or a related oxide or salt substance. Composite radiopaque materials may contain at least one element having an atomic number, preferably, higher than about 22. Other radiopaque materials may include gold, platinum, tantalum, metallic biomaterial alloys for coating, and small particles of these materials, preferably, less than 10 microns in size for compounding. For compounding radiopaque constituents and bioabsorbable resins to make extruded bioabsorbable-radiopaque filament, the weight percentage of radiopaque resins to bioabsorbable resins ranges from about 1 percent to about 80 percent. For compounding radiopaque metallic fillers and bioabsorbable resins to make extruded bioabsorbable-radiopaque filament, the weight percentage of radiopaque metallic fillers to bioabsorbable resins ranges from about 1 percent to about 40 percent. The preferred weight percentage of bismuth trioxide and barium sulfate in PLLA filament is a minimum of about 10%. Preferred embodiments of the bioabsorbable-radiopaque marker are set forth below in Table 2.



Table 2

Marker Type	Function	Devices	Preferred Marker Metal Radiopaque Constituents	Metal Radiopaque Constituent Loading, Weight %	Preferred Marker Organic Radiopaque Constituent	Organic Radiopaque Constituent Loading, Weight %	Preferred Marker Matrix Materials For Fast Absorption	Preferred Marker Matrix Materials For Slow Absorption
threading on helix	mark overall stent length, location in vessel	braided tubular stents, filters, occlusion, valves	Ti, Ta, Zr, Pt	Ti, Zr = 15-40 Ta, Pt = 1-20	Br, I, Ba, Bi	Br, I = 40-80 Bi, Ba = 10-80	PGA, polydioxanone	PLLA, PDLA
threading around circumference	mark stent ends, location in vessel, covering length, expansion	braided tubular stents, filters, occlusion, valves, stent grafts	Ti, Ta, Zr, Pt	Ti, Zr = 15-40 Ta, Pt = 1-20	Br, I, Ba, Bi	Br, I = 40-80 Bi, Ba = 10-80	PGA, polydioxanone	PLLA, PDLA
threading on straight axial line	mark overall stent length, location in vessel	braided tubular stents, filters, occlusion, valves, stent grafts	Ti, Ta, Zr, Pt	Ti, Zr = 15-40 Ta, Pt = 1-20	Br, I, Ba, Bi	Br, I = 40-80 Bi, Ba = 10-80	PGA, polydioxanone	PLLA, PDLA
pigtail rings	mark stent ends or center, location in vessel, expansion	braided tubular stents, filters, occlusion, valves, stent grafts	Ti, Ta, Zr, Pt	Ti, Zr = 15-40 Ta, Pt = 1-20	Br, I, Ba, Bi	Br, I = 40-80 Bi, Ba = 10-80	PGA, polydioxanone	PLLA, PDLA
coils	mark stent ends or center, location in vessel, expansion	braided tubular stents, filters, occlusion, valves, stent grafts	Ti, Ta, Zr, Pt	Ti, Zr = 15-40 Ta, Pt = 1-20	Br, I, Ba, Bi	Br, I = 40-80 Bi, Ba = 10-80	PGA, polydioxanone	PLLA, PDLA
knots	mark stent ends or center, location in vessel, expansion	braided tubular stents, filters, occlusion, valves, stent grafts	Ti, Ta, Zr, Pt	Ti, Zr = 15-40 Ta, Pt = 1-20	Br, I, Ba, Bi	Br, I = 40-80 Bi, Ba = 10-80	PGA, polydioxanone	PLLA, PDLA

[0046] The column for marker type in Table 2 contains a description of the physical aspects of the marker such as a strand threaded in and out of the braided stent interstices, following a wire helix or in and out of the braided stent inter-

stices around the circumference, or in and out of the braided stent interstices in a straight line in the axial orientation. An interstice is the location where two stent wires in the braid cross over one another. The function of the marker is described in Table 2 to indicate how the marker is used in the endoprosthesis, for example, to indicate the ends of a stent or to allow radiographic visualization of the stent changing from a constrained condition to an expanded condition as it is deployed. A list of devices where the marker could be incorporated is provided in Table 2 and generally contains various types of intraluminal endoprosthesis. The preferred metal radiopaque constituents (Ta, Pt, Zr, Ti) are known to be biocompatible and have relatively high atomic numbers and linear attenuation coefficients. These elements would be added to the bioabsorbable polymer to make the material radiopaque and suitable for radiographic marking. The adjacent column, Metal Radiopaque Constituent Loading, Weight %, indicates the preferred range of loading of the metal radiopaque constituents into the bioabsorbable polymer to make it sufficiently radiopaque, such as from about 1 to about 20 weight percent tantalum or platinum compounded or coated onto the polymer. The same type of information is given in the next two columns for organic radiopaque constituents. The marker may be made with either metal or organic constituents, with metal being preferred for thin markers and organics being more appropriate for thicker markers where higher loadings can be tolerated (so as to not weaken the marker significantly). The last two columns in the table contain preferred absorbable polymers for the marker matrix material. PLLA and PDLA are preferred for slow-absorbing markers, because the degradation rate of these polymers is rather slow (months to years). PGA and polydioxanone are preferred for fast-absorbing markers because the degradation rate of these polymers is rather fast (weeks to months)

[0047] For description purposes, the markers of the invention can be segregated into types; threaded and discrete bioabsorbable-radiopaque markers. A threaded marker is generally a strand or strands of material having radiopacity which is incorporated within the implantable device by interweaving or interbraiding the strand through the struts or wires of the endoprosthesis. A discrete bioabsorbable-radiopaque marker is generally a bioabsorbable-radiopaque polymer strand of material which is securely attached to a localized region of the implantable device and does not significantly extend over a large portion of the device.

[0048] An example of a threaded marker in a braided wire tubular stent is a bioabsorbable-radiopaque polymer strand loaded with a radiopaque constituent that is woven in and out of the wire crossing points following the helical path of one individual wire strand in the stent.

[0049] An example of a discrete bioabsorbable-radiopaque marker is a coil, knot, or ring of a bioabsorbable-radiopaque polymer strand around a feature of a stent, such as a stent wire crossing point. The strand is wrapped, coiled, or tied around the stent wire and thereby is mechanically attached to the device. The strand ends are clipped off such that the marker is present as a small, tightening around a feature of the stent. The stent with the attached markers is loaded and deployed from the delivery.

[0050] The absorbable radiopaque markers are used in a variety of intraluminal endoprostheses such as stents, grafts, filters, occlusive devices, and valves. The endoprostheses are implanted in airways, the digestive system, and the vascular system. When the markers are implanted and exposed to body fluids the absorbable polymer matrix undergoes degradation and eventually disintegrates releasing the nondegradable radiopaque constituents into the body. If the endoprosthesis and markers have been fully incorporated in the vessel wall, the radiopaque substances will be contained within the local tissue (as with a stent). If the endoprosthesis and markers are not ingrown and incorporated, the radiopaque substances may be released into the body fluid. The release is of little concern in the digestive system, because the small concentration of particles liberated are likely to have little affect on bile and would be quickly excreted. The release of particles into the vascular system is less desirable but this can be avoided by using low loading percentages and fine particle sizes for vascular device indications.

[0051] The function of the absorbable threaded radiopaque marker is to indicate on a radiographic image the location of the stent within the treatment site and the length of the expanded stent can be determined by measuring the length of the marker as it follows the stent shape if the marker was threaded along a stent wire held or axially along a line in the stent. The marker can be threaded circumferentially at each end of the stent covering in a covered stent or stent-graft to indicate the location of the radiolucent covering material. The stent expansion during deployment can be observed radiographically by watching the radiopaque marker helical or circumferential strand open up as the self-expanding stent is released from its radially constrained state.

[0052] Discrete bioabsorbable-radiopaque markers have the same functional purpose as the threaded markers, but they can be more easily used to mark the specific locations of features of interest on the stent. For example, a discrete bioabsorbable-radiopaque marker can be added to the center of the stent length to aid the physician in centering the stent within the stricture. Discrete bioabsorbable-radiopaque markers could be used to attach covering fabrics or films to stents to make stent grafts so that the location of the covering on the stent could be determined radiographically.

[0053] The discrete bioabsorbable-radiopaque markers can be made from biocompatible absorbable polymers containing elements with relatively high atomic numbers such as titanium, tantalum, zirconium, and platinum. The radiopaque elements can be added by metallurgically alloying or by making clad composite structures. Radiopaque constituents may be filled into hollow cores, cavities or pores in the polymer matrix. Organic radiopaque powders con-

taining elements or salts or oxides of elements such as bromine, iodine, iodide, barium, and bismuth could be used instead of metal powders.

[0054] The amount of radiopaque constituent that is added to the absorbable polymer matrix is generally from about 1-80 weight percent, but the specific loading depends upon the atomic number of the radiopaque constituent and the thickness of the marker. Metallic elements like tantalum and platinum which have high atomic numbers can be loaded in small percentages (about 1-20 weight percent) while metallic elements with lower atomic numbers such as titanium and zirconium have to be loaded in higher percentages (about 20-40%). Organic radiopaque constituents with relatively low atomic numbers like iodine and bromine require loading percentages of from about 40-80 weight percent while organics with higher atomic numbers could be as low as 10% in thick markers. It is desirable to have the radiopaque constituent particle size be less than 10 microns so that when dispersed into the body the particles will not be so large as to cause obstruction or embolization.

#### Example 1

[0055] An absorbable threaded radiopaque marker can be in the form of a strand of poly ( $\alpha$ -hydroxy acid) polymer containing radiopaque elements, oxides, or salts of elements with atomic numbers of from about 22 to about 83 interwoven or interbraided along a helical, circumferential, or axial orientation on an endoprosthesis such as a stent, stent-graft, graft, filter, occlusive device, and valve. The radiopaque material has a linear attenuation coefficient of from about  $10 \text{ cm}^{-1}$  at 50 KeV to about  $120 \text{ cm}^{-1}$  at 50 KeV.

#### Example 2

[0056] An absorbable threaded radiopaque marker can be in the form of a strand of poly ( $\alpha$ -hydroxy acid) polymer containing radiopaque elements, oxides, or salts of elements with atomic numbers of from about 22 to about 83 disposed on one or more surfaces of a endoprosthesis such as a stent, stent-graft, graft, filter, occlusive device, and valve. The radiopaque material has a linear attenuation coefficient of from about  $10 \text{ cm}^{-1}$  at 50 KeV to about  $120 \text{ cm}^{-1}$  at 50 KeV.

#### Example 3

[0057] An absorbable threaded radiopaque marker can be in the form of a strand of poly ( $\alpha$ -hydroxy acid) polymer containing radiopaque elements with atomic numbers of from about 22 to about 23, loaded into hollow cores, cavities, or pores of the polymer portion and disposed on a endoprosthesis such as a stent, stent-graft, graft, filter, occlusive device, and valve. The radiopaque material has a linear attenuation coefficient of from about  $10 \text{ cm}^{-1}$  at 50 KeV to about  $120 \text{ cm}^{-1}$  at 50 KeV.

#### Example 4

[0058] An absorbable threaded radiopaque can be a coated or clad composite marker strand of poly ( $\alpha$ -hydroxy acid) polymer and radiopaque metallic elements with atomic numbers of from about 22 to about 83, preferably titanium, tantalum, zirconium, and disposed on an endoprosthesis such as a stent, stent-graft, graft, filter, occlusive device, and valve. The radiopaque material has a linear attenuation coefficient of from about  $10 \text{ cm}^{-1}$  at 50 KeV to about  $120 \text{ cm}^{-1}$  at 50 KeV.

#### Example 5

[0059] An absorbable threaded radiopaque marker can be in the form of a strand of poly ( $\alpha$ -hydroxy acid) polymer monofilament, ribbon, or multifilament wire containing radiopaque metallic elements with atomic numbers of from about 22 to about 83, preferably compounded or coated with titanium, tantalum, zirconium, and platinum metal powders or bromine, iodine, iodide, barium, and bismuth element, oxides or salts disposed on a endoprosthesis such as a stent, stent-graft, graft, filter, occlusive device, and valve. The radiopaque material has a linear attenuation coefficient of from about  $10 \text{ cm}^{-1}$  at 50 KeV to about  $120 \text{ cm}^{-1}$  at 50 KeV.

#### Example 6

[0060] An absorbable threaded radiopaque marker can be in the form of poly ( $\alpha$ -hydroxy acid) polymer matrix composite strand containing radiopaque metallic elements with atomic numbers of from about 22 to about 83, preferably titanium, tantalum, zirconium, and platinum metal powders or bromine, iodine, iodide, barium, and bismuth element,

oxides or salt powders disposed on an endoprosthesis such as a stent, stent-graft, graft, filter, occlusive device, and valve. The radiopaque material has a linear attenuation coefficient of from about  $10 \text{ cm}^{-1}$  at 50 KeV to about  $120 \text{ cm}^{-1}$  at 50 KeV.

#### 5 Example 7

[0061] A discrete bioabsorbable-radiopaque marker can be in the form of poly ( $\alpha$ -hydroxy acid) polymer containing radiopaque metallic elements with atomic numbers of from about 22 to about 83, preferably titanium, tantalum, zirconium, and platinum attached by wrapping, coiling, or tying around features within an endoprosthesis such as a stent, stent-graft, graft filter, occlusive device, and valve such that the marker is attached and bioabsorbably removable from the endoprosthesis. The radiopaque material has a linear attenuation coefficient of from about  $10 \text{ cm}^{-1}$  at 50 KeV to about  $120 \text{ cm}^{-1}$  at 50 KeV.

[0062] Reference is made to FIGS. 8a-8c illustrating alternative embodiments of a portion of a bioabsorbable-radiopaque marker 14. The bioabsorbable-radiopaque marker 14 may have at least one portion for temporary containment of a radiopaque material. The radiopaque material may be disposed in one or more hollow, cavity or pore portions in the marker 14. For example, FIG. 8a shows a solid bioabsorbable-radiopaque marker 14. As shown in FIGS. 8b-8c, the bioabsorbable-radiopaque marker 14, may receive a radiopaque core 13 disposed in the once hollow 15 portion. The radiopaque core 13 may be slowly released from the open ends 14a, 14b of the hollow portion 15 into the body. Alternatively, the radiopaque core 13 may be released from the radiopaque core 13 through pores in the walls of the marker 14 into the body.

[0063] FIG. 9 is a illustration of a bioabsorbable-radiopaque marker 14 having pores 35. The pores may connect to a reservoir of radiopaque material in a cavity 25 or hollow 15 area or the individual pores 35 may be filled with radiopaque material. The pores 35 allow the radiopaque material disposed in the marker 14 to exit from the marker 14 over a period of time.

[0064] The radiopaque material may be solid or include a bioabsorbable casing surrounding a liquid, solid, gel, powder, or combination thereof and be held in place in a hollow portion 15, cavity 25, or porous 35 portion by a relatively weak bioabsorbable adhesive, bioabsorbable gelatin, friction, or by other mechanical or chemical means known in the art. The radiopaque material may be designed to disperse from the bioabsorbable-radiopaque marker 14 after a predetermined period of time. The radiopaque material preferably has at least one element with an atomic number of from about 22 to about 83 and is removably-attachable in at least one hollow 15, cavity 25, or porous 35 portions in the marker 14. The bioabsorbable-radiopaque marker 14 may further comprise one or more walls 30 including walls between hollow 15, cavity 25, and porous 35 portions, proximal and distal walls, and combinations thereof that are adapted to bioabsorb *in vivo*.

[0065] Reference is made to FIGS. 10a-10d illustrating different embodiments of the bioabsorbable-radiopaque marker 14 having hollow 15, cavity 25, porous 35 portions, or combinations thereof filled with a nontoxic radiopaque material. FIG. 10a shows a bioabsorbable-radiopaque marker 14 with a hollow 15 portion filled with radiopaque material and having at least one of the proximal or distal ends open; FIG. 10b shows a bioabsorbable-radiopaque marker 14 with a cavity 25 portion filled with radiopaque material having closed ends; FIG. 10c shows a bioabsorbable-radiopaque marker 14 with porous 35 portions filled with radiopaque material; and FIG. 10d shows a bioabsorbable-radiopaque marker 14 with combinations of hollow 15, cavity 25, and porous 35 portions filled with radiopaque material. The bioabsorbable-radiopaque marker 14 reacts with body fluids and decomposes and then the constituents are absorbed or excreted from the body.

[0066] FIG. 11 illustrates discrete bioabsorbable-radiopaque markers 14 made by forming small rings or coils of bioabsorbable-radiopaque filament around features of the implantable endoprosthesis 16. Relatively small and discrete filament loops (pigtail) bioabsorbable-radiopaque markers 14 are shown at the wire crossing points on the tubular braid.

[0067] FIG. 12 illustrates the detail bounded by the dashed-line circle in FIG. 11 showing a bioabsorbable-radiopaque marker 14 around one implantable endoprosthesis 16 wire crossing point.

[0068] FIG. 13 illustrates the bioabsorbable-radiopaque marker 14 of FIG. 12 and FIG. 13 and shows filament ends 14a, 14b which simply pass over each other to form an enclosed loop that is further preferably knotted, twisted, or tied at ends 14a, 14b. The bioabsorbable-radiopaque markers 14 may be relatively small and comprise a single loop or pigtail of filament around one filament crossing point, filament, an embolization coil, or the like. The bioabsorbable-radiopaque marker 14 is preferably made of a PGA, Polydioxane, PLLA, PDLA, or combinations thereof. Biocompatible radiopaque metal constituents preferably include titanium, zirconium, tantalum, and platinum. Preferred organic radiopaque constituents include bromine, barium, bismuth, iodine, or combinations thereof.

[0069] The bioabsorbable-radiopaque marker 14 is preferably formed from an elongate member such as a filament and shaped accordingly onto the implantable endoprosthesis 16. The bioabsorbable-radiopaque marker 14 advantageously allows custom marking of the implantable endoprosthesis 16 without the need to acquire preformed marker bands or to devise a complicated manufacturing operation. The bioabsorbable-radiopaque markers 14 may be easily

and quickly added to the implantable endoprosthesis 16. Also, only small, specific sites are marked by the bioabsorbable-radiopaque marker 14 so a minimum amount of foreign body material would be added to the implantable endoprosthesis 16.

[0070] The bioabsorbable-radiopaque markers 14 should preferably be smaller than the size of the element in the implantable endoprosthesis 16. A smaller diameter bioabsorbable-radiopaque marker 14 should fit through most weaves, be deformable, and may be cut to size.

[0071] Reference is made to FIGS. 12-13 illustrating discrete bioabsorbable-radiopaque markers 14 looped one or more times about a filament or filament crossing point to prevent release therefrom. The ends 14a, 14b are clipped and positioned to lie in a plane parallel to the longitudinal axis of the implantable endoprosthesis 16. The bioabsorbable-radiopaque marker 14 may be disposed on one or more filament crossing or every other filament crossing point around the circumference of the braid in one circular transverse plane. The bioabsorbable-radiopaque markers 14 may be positioned to form one or more circumferential rings on the implantable endoprosthesis 16. Alternatively, the bioabsorbable-radiopaque markers 14 may be positioned along an embolization occlusion coil intravascular device or filament at predetermined locations as illustrated in FIG. 15. The ends 14a, 14b may then be tied, twisted, knotted, or adhesively connected together and thereafter clipped and positioned to lie in an unobtrusive low-profile position.

[0072] It will be evident from considerations of the foregoing that the bioabsorbable-radiopaque marker 14 may be constructed using a number of methods and materials, in a wide variety of sizes and styles for the greater efficiency and convenience of a user.

[0073] A bioabsorbable marker that may advantageously be used in conjunction with the present invention is disclosed in J. Stinson's and Claude Clerc's United States Patent Application entitled "Radiopaque Markers And Methods Of Using Same", Serial No. 08/905,821, filed concurrently herewith, and commonly assigned to the assignee of this application.

[0074] A bioabsorbable stent that may advantageously be used in conjunction with the present invention is disclosed in J. Stinson's United States Patent Application entitled "Bioabsorbable Implantable Endoprosthesis With Reservoir And Method Of Using Same", Serial No. 08/905,806, filed concurrently herewith and commonly assigned to the assignee of this application.

[0075] Another bioabsorbable stent that may advantageously be used in conjunction with the present invention is disclosed in J. Stinson's United States Patent Application entitled "Bioabsorbable Self-Expanding Stent", Serial No. 08/904,467, filed concurrently herewith and commonly assigned to the assignee of this application.

[0076] The above described embodiments of the invention are merely descriptive of its principles and are not to be considered limiting. Further modifications of the invention herein disclosed will occur to those skilled in the respective arts and all such modifications are deemed to be within the scope of the invention as defined by the following claims.

## Claims

1. An implantable endoprosthesis and bioabsorbable radiopaque marker system comprising:

an implantable endoprosthesis (16) adapted to be disposed in a body lumen; and  
at least one marker (14) having a proximal end, a distal end, and a thickness, the marker (14) comprising bioabsorbable material and radiopaque material and is disposed on or adjacent the endoprosthesis (16), the marker (14) adapted to degrade *in vivo* whereby the bioabsorbable material is metabolized through or excreted from the body and the radiopaque material is excreted from or stored in the body.

2. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein the bioabsorbable material comprises a polymer or copolymer.

3. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein the bioabsorbable material consists of a material selected from the group consisting of poly-L-lactide, poly-D-lactide, polyglycolide, polydioxione, polycaprolactone, and polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, poly(hydroxybutyrate), polyanhydride, polyphosphoester, poly(amino acids), poly(alpha-hydroxy acid) and combinations thereof

4. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein the radiopaque material has a linear attenuation coefficient of from about  $10 \text{ cm}^{-1}$  at 50 KeV to about  $120 \text{ cm}^{-1}$  at 50 KeV.

5. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein the marker (14) has an average thickness of from about 20 microns to about 500 microns and the radiopaque material includes at least one element with an atomic number of from about 22 to about 83.

6. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein the radiopaque material consists of a material selected from the group consisting of barium sulfate, bismuth trioxide, bromine, iodine, iodide, titanium oxide, zirconium oxide, tantalum, and combinations thereof.
- 5 7. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein the radiopaque material is a oxide or salt material.
8. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein one of the bioabsorbable material or radiopaque material is coated or compounded with the other and wherein the radiopaque  
10 material has a linear attenuation coefficient of from about  $10 \text{ cm}^{-1}$  at 50 KeV to about  $120 \text{ cm}^{-1}$  at 50 KeV.
9. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein the marker (14) has a weight percent of the radiopaque material in the bioabsorbable material of from about 1% to about 80%.
- 15 10. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein the bioabsorbable material consists of PLLA and the radiopaque material consists of bismuth trioxide and the weight percent of the bismuth trioxide in the PLLA is at least about 10%.
11. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein the bioabsorbable material consists of PLLA and the radiopaque material is barium sulfate wherein the weight percentage of the  
20 barium sulfate in the PLLA is at least about 10%.
12. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein the marker (14) substantially degrades in less than about 3 years.
- 25 13. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein the bioabsorbable material consists of polylactide and the radiopaque material consists of a material selected from the group consisting of barium sulfate, bismuth trioxide, iodine, iodide, and combinations thereof whereby the marker (14) substantially degrades in film about 1 year to about 2 years.
- 30 14. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein the bioabsorbable material consists of a material selected from the group consisting of poly-L-lactide, poly-D-lactide, polyglycolide, and combinations thereof and the radiopaque material consists of material selected from the group consisting of barium sulfate, bismuth trioxide, bromine, iodine, iodide, and combinations thereof whereby the marker (14) sub-  
35 stantially degrades in from about 3 months to about 1 year.
15. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein the bioabsorbable material consists of a material selected from the group consisting of polyglycolide, polygluconate, polydioxanone, and combinations thereof and the radiopaque material consists of a material selected from the group  
40 consisting of barium sulfate, bismuth trioxide, bromine, iodine, iodide, and combinations thereof whereby the marker (14) substantially degrades in from about 1 week to about 3 months.
16. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein the marker (14) is in a form selected from the group consisting of mono-filament, multi-filament, thread, ribbon, suture, and combinations thereof.
- 45 17. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein the marker (14) includes one or more portion selected from the group consisting of hollow (15), cavity (25), porous (35), and combinations thereof and the radiopaque material is disposed therein.
- 50 18. The implantable endoprosthesis and temporary bioabsorbable-radiopaque marker system of claim 1 wherein the marker (14) has radiopacity for a predetermined amount of time.
19. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein the endoprosthesis (16) is selected from the group consisting of stent, stent-graft, graft, filter, occlusive device, and valve.
- 55 20. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 1 wherein the endoprosthesis (16) has a tubular, radially expandable structure and axially flexible structure including a plurality of the elon-

gate elements which are interwoven in a braid-like configuration.

21. An implantable endoprosthesis and bioabsorbable-radiopaque marker system comprising:

5 an implantable endoprosthesis (16) adapted to be disposed in a body lumen (12); and  
at least one elongated marker (14) adapted to be disposed on or adjacent the endoprosthesis (16), the marker  
(14) comprising a proximal end, distal end, thickness, bioabsorbable material, radiopaque material having a linear  
attenuation coefficient of from about  $10 \text{ cm}^{-1}$  at 50 KeV to about  $120 \text{ cm}^{-1}$  at 50 KeV, the marker (14) having  
10 at least one hollow (15), cavity (25), or porous (35) portion wherein the radiopaque material is disposed therein  
and wherein the bioabsorbable material at least partially contains the radiopaque material.

22. The implantable endoprosthesis and bioabsorbable-radiopaque marker system of claim 21 wherein the radiopaque  
material is a liquid, solid, powder, gel, particle, or combinations thereof.

15 23. A method of marking an implantable endoprosthesis comprising the steps of:

disposing at least one elongate marker (14) on or adjacent to at least a portion of a implantable endoprosthesis  
(16), the marker (14) from about 20 weight percent to about 99 weight percent of a bioabsorbable polymer and  
from about 1 weight percent to about 80 weight percent of a radiopaque material, the radiopaque material comprising  
20 liquid or particles, the particles having an average diameter less than about 200 microns and a maximum  
diameter less than about 500 microns, the radiopaque material having a linear attenuation coefficient of  
from about  $10 \text{ cm}^{-1}$  at 50 KeV to about  $120 \text{ cm}^{-1}$  at 50 KeV;  
disposing the endoprosthesis (16) and marker (14) in a delivery system (10); inserting the delivery system (10)  
in a body lumen (12);  
25 deploying the endoprosthesis (10) and marker (14) from the delivery system (10) into a body lumen (12); and  
allowing the polymer to bioabsorb or excrete whereby the radiopaque material subsequently or simultaneously  
at least partially disperses from the endoprosthesis (16).

24. A temporary bioabsorbable-radiopaque marker comprising:

30 a marker (14) having an average thickness less than about 500 microns and consisting of a bioabsorbable  
material and a radiopaque material, the radiopaque material having a linear attenuation coefficient of from  
about  $10 \text{ cm}^{-1}$  at 50 KeV to about  $120 \text{ cm}^{-1}$  at 50 KeV wherein the marker (14) is adapted to be disposed in a  
body lumen (12) and degrade *in vivo*.

35 25. The temporary bioabsorbable-radiopaque marker of claim 24 wherein the marker (14) is elongate and has a proximal  
end and a distal end.

26. A bioabsorbable-radiopaque marker comprising:

40 an elongate element (14) adapted to be disposed in a body lumen and used as a surgical guide, the element  
(14) consisting of a material selected from the group consisting of a bioabsorbable material, a radiopaque  
material, and combinations thereof, the element (14) having a weight percent, W, of the radiopaque material in  
the bioabsorbable material, and an average thickness, T, over the length of the elongate element (14) wherein  
45 the weight percent, W, is equal to about:

(i)  $[10 + ((950 \times T(\text{measured in mm}) - 208.5)) \pm 5]$  for radiopaque material having atomic weight 20-100;  
(ii)  $((950 \times T(\text{measured in mm})) - 208.5) \pm 5$  for radiopaque material having atomic weight of 100 to 150 up  
to a maximum of 80 weight percentage; or  
50 (iii)  $(((950 \times T(\text{measured in mm})) - 208.5) - 10) \pm 5$  for radiopaque material having atomic weight greater than  
150  
wherein the minimum W is about 1 and the maximum W is about 80.

27. A marker (14) comprising:

55 from about 20 weight percent to about 99 weight percent of a bioabsorbable polymer; and from about 1 weight  
percent to about 80 weight percent of a radiopaque material, the radiopaque material comprising at least one  
of a liquid or particle having an average particle diameter less than about 8 microns and a maximum particle

## EP 0 894 503 A2

diameter less than about 10 microns, the radiopaque material having a linear attenuation coefficient of from about  $10 \text{ cm}^{-1}$  at 50 KeV to about  $120 \text{ cm}^{-1}$  at 50 KeV.

5

10

15

20

25

30

35

40

45

50

55



FIG. 1




FIG. 2




FIG. 3a




FIG. 3b




FIG. 3c




FIG. 4




FIG. 5





FIG. 6






FIG. 7a




FIG. 7b




FIG. 7c




FIG. 7d



FIG. 7e



**FIG. 8a**



**FIG. 8b**

FIG. 8c








FIG. 9



**FIG. 10a**



**FIG. 10b**




FIG. 10c




FIG. 10d




FIG. 11




FIG. 12




FIG. 13





FIG. 14





(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:  
27.09.2000 Bulletin 2000/39

(51) Int. Cl.<sup>7</sup>: **A61L 27/00, A61L 27/50**

(43) Date of publication A2:  
03.02.1999 Bulletin 1999/05

(21) Application number: **98201865.7**

(22) Date of filing: **08.06.1998**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(72) Inventor:  
**Stinson, Jonathan Swift**  
**Plymouth, Minnesota 55447 (US)**

(30) Priority: **01.08.1997 US 904951**

(74) Representative:  
**Kenyon, Sarah Elizabeth**  
**Miller Sturt Kenyon**  
**9 John Street**  
**London WC1N 2ES (GB)**


(71) Applicant: **SCHNEIDER (USA) INC.**  
**Plymouth, Minnesota 55442 (US)**

(54) **Bioabsorbable marker having radiopaque constituents and method of using same**

(57) A temporary bioabsorbable-radiopaque marker (14) for use on an implantable endoprosthesis (16). The bioabsorbable-radiopaque marker (14) is adapted to be disposed on or adjacent an implantable endoprosthesis

(16) in a body lumen (12) for a predetermined amount of time until the bioabsorbable and radiopaque materials are absorbed or dispersed in the body.

**FIG. 5**





European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 98 20 1865

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	EP 0 615 769 A (KABUSHIKIKAISHA IGAKI IRYO SEK) 21 September 1994 (1994-09-21)  * column 5, line 24 - line 38 * * examples 1,2 * * claims *	1-9, 11-16, 18-20, 24,25	A61L27/00 A61L27/50
X	US 5 423 885 A (WILLIAMS MICHAEL S) 13 June 1995 (1995-06-13)  * column 3, line 22 - line 29 * * column 3, line 61 - column 4, line 3 *	1-9, 12-15, 18-20,24	
X	US 5 085 629 A (GOLDBERG JAY ET AL) 4 February 1992 (1992-02-04)  * column 2, line 52 - line 62 * * column 4, line 46 - line 54 *	1-9, 12-15, 18-20, 23,24	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			A61L A61F A61B
The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>31 July 2000</b>	Examiner <b>Muñoz, M</b>
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons Δ : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.92 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 20 1865

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

31-07-2000

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0615769	A	21-09-1994	JP 6086827 A	29-03-1994
			US 5762625 A	09-06-1998
			WO 9405364 A	17-03-1994
US 5423885	A	13-06-1995	US 5593434 A	14-01-1997
			CA 2087132 A	01-08-1993
			DE 69315863 D	05-02-1998
			DE 69315863 T	16-04-1998
			DE 69326625 D	04-11-1999
			DE 69326625 T	13-01-2000
			EP 0554082 A	04-08-1993
			EP 0749730 A	27-12-1996
			JP 6000221 A	11-01-1994
US 5085629	A	04-02-1992	AU 633361 B	28-01-1993
			AU 6364390 A	11-04-1991
			CA 2025626 A	28-03-1991
			EP 0420541 A	03-04-1991
			JP 3205059 A	06-09-1991

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82